L2167
L-165,041
≥98% (HPLC), powder
別名:
4-[3-(4-アセチル-3-ヒドロキシ-2-プロピルフェノキシ)プロポキシ]フェノキシ酢酸
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C22H26O7
CAS番号:
分子量:
402.44
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
protect from light, under inert gas
assay
≥98% (HPLC)
form
powder
storage condition
protect from light, under inert gas
color
off-white
mp
127-128 °C (lit.)
solubility
DMSO: >10 mg/mL
originator
GlaxoSmithKline
storage temp.
2-8°C
SMILES string
CCCc1c(O)c(ccc1OCCCOc2ccc(OCC(O)=O)cc2)C(C)=O
InChI
1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)
InChI key
HBBVCKCCQCQCTJ-UHFFFAOYSA-N
Gene Information
human ... PPARD(5467)
Application
L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts.
Biochem/physiol Actions
PPARβ(PPARδ)の選択的アゴニストです。
L-165041 dose-dependently blocks rat vascular smooth muscle cell (VSMC) proliferation and migration by inducing the cell cycle arrest. It has the potential to treat pathological cardiovascular conditions, such as restenosis and atherosclerosis. L-165041 also effectively inhibits the progression of diabetic nephropathy. It exhibits anti-apoptosis and anti-angiogenic effects.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under L-165,041
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)